Ontology highlight
ABSTRACT: Objectives
To examine company characteristics associated with better transparency and to apply a tool used to measure and improve clinical trial transparency among large companies and drugs, to smaller companies and biologics.Design
Cross-sectional descriptive analysis.Setting and participants
Novel drugs and biologics Food and Drug Administration (FDA) approved in 2016 and 2017 and their company sponsors.Main outcome measures
Using established Good Pharma Scorecard (GPS) measures, companies and products were evaluated on their clinical trial registration, results dissemination and FDA Amendments Act (FDAAA) implementation; companies were ranked using these measures and a multicomponent data sharing measure. Associations between company transparency scores w
SUBMITTER: Axson S
PROVIDER: S-EPMC8291313 | biostudies-literature | 2021 Jul
REPOSITORIES: biostudies-literature